- Home
- CNR vs TGTX Comparison
CNR vs TGTX Comparison
Compare CNR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNR
- TGTX
- Stock Information
- Founded
- CNR 1864
- TGTX 1993
- Country
- CNR United States
- TGTX United States
- Employees
- CNR N/A
- TGTX N/A
- Industry
- CNR Coal Mining
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CNR Energy
- TGTX Health Care
- Exchange
- CNR Nasdaq
- TGTX Nasdaq
- Market Cap
- CNR 3.8B
- TGTX 4.2B
- IPO Year
- CNR N/A
- TGTX 1995
- Fundamental
- Price
- CNR $72.92
- TGTX $32.33
- Analyst Decision
- CNR Strong Buy
- TGTX Strong Buy
- Analyst Count
- CNR 4
- TGTX 4
- Target Price
- CNR $94.75
- TGTX $42.50
- AVG Volume (30 Days)
- CNR 628.0K
- TGTX 2.0M
- Earning Date
- CNR 08-05-2025
- TGTX 11-03-2025
- Dividend Yield
- CNR 0.55%
- TGTX N/A
- EPS Growth
- CNR N/A
- TGTX N/A
- EPS
- CNR 0.51
- TGTX 0.36
- Revenue
- CNR $3,275,589,000.00
- TGTX $454,069,000.00
- Revenue This Year
- CNR $92.77
- TGTX $82.58
- Revenue Next Year
- CNR $9.20
- TGTX $44.99
- P/E Ratio
- CNR $141.65
- TGTX $89.78
- Revenue Growth
- CNR 47.13
- TGTX 30.96
- 52 Week Low
- CNR $58.19
- TGTX $21.16
- 52 Week High
- CNR $134.59
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- CNR 50.09
- TGTX 60.04
- Support Level
- CNR $71.83
- TGTX $31.34
- Resistance Level
- CNR $75.67
- TGTX $32.57
- Average True Range (ATR)
- CNR 2.18
- TGTX 1.13
- MACD
- CNR 0.10
- TGTX 0.56
- Stochastic Oscillator
- CNR 50.85
- TGTX 81.57
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.